Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
FDA: Parenteral nutrition for patients requiring total or supplemental nutrition when oral or enteral feeding is not possible, insufficient, or contraindicated.,Off-label: None commonly recognized.
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 m L/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 m L/kg/day of TRAVASOL 3.5%.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids are metabolized via deamination, transamination, and urea cycle in the liver. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Electrolytes are not metabolized.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Minimal for amino acids (<10% bound to albumin); electrolytes are not protein-bound.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids: 0.3-0.5 L/kg (total body water). Electrolytes: Na+ 0.6 L/kg, K+ 4 L/kg, Mg2+ 0.5 L/kg, Cl- 0.3 L/kg, acetate<0.1 L/kg.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
IV: 100%. Not administered by other routes.
Intravenous: 100%.
In acute kidney injury or chronic kidney disease with GFR <30 m L/min/1.73 m², restrict protein intake to 0.6-0.8 g/kg/day; monitor electrolytes closely. For GFR 30-60 m L/min/1.73 m², consider reducing dose to 0.8-1.0 g/kg/day. No specific guidelines for hemodialysis.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
In severe hepatic impairment (Child-Pugh C), use with caution; consider branched-chain amino acid enriched solutions; reduce amino acid dose to 0.5-1.0 g/kg/day. Child-Pugh B: no specific adjustment, but monitor for hyperammonemia.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Neonates and infants: 2-3 g amino acids/kg/day; children 1-12 years: 1.5-2 g/kg/day. Administer as continuous IV infusion; adjust based on nitrogen balance and growth.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
No specific geriatric adjustment; use lowest effective dose, monitor renal function and fluid status due to increased risk of fluid overload and electrolyte imbalances. Typical dose: 0.8-1.0 g amino acids/kg/day.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are at greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Use only if solution is clear and container undamaged.,Risk of infection and sepsis from catheter use.,Monitor fluid and electrolyte balance, blood glucose, liver function, and renal function.,Aluminum toxicity risk (see black box warning).,Sulfite-free formulation reduces risk of allergic reactions in sulfite-sensitive patients.,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Patients with severe electrolyte imbalances or fluid overload.,Anuria or end-stage renal disease without dialysis.,Inborn errors of amino acid metabolism.,Severe liver disease with hepatic encephalopathy.
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No direct food interactions. Parenteral nutrition bypasses the gastrointestinal tract. Avoid oral intake unless clinically indicated. Monitor blood glucose as amino acids may affect glucose metabolism.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
Amino acid and electrolyte solutions are generally considered low risk for teratogenicity. No specific fetal risks have been identified in animal studies; however, maternal malnutrition or electrolyte imbalances may indirectly affect fetal development. Use during pregnancy only if clearly needed.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Amino acids and electrolytes are normal components of breast milk. TRAVASOL 3.5% is unlikely to affect the nursing infant. M/P ratio not available; however, infusion of balanced amino acids and electrolytes is considered compatible with breastfeeding.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
No specific dose adjustments in pregnancy. Use standard dosing based on clinical need, but caution in conditions predisposing to fluid/electrolyte imbalance (e.g., preeclampsia).
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
TRAVASOL 3.5% is a parenteral nutrition solution providing amino acids and electrolytes. Monitor serum electrolytes, renal function, and acid-base balance. Do not administer simultaneously with blood via same IV line due to risk of agglutination. Use inline filter (0.22 micron) during administration. Discontinue if signs of hypersensitivity or infection occur.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This solution is given intravenously to provide nutrition when you cannot eat.,Tell your healthcare provider if you have any allergies, especially to sulfites (this product is sulfite-free).,Inform your provider if you experience fever, chills, redness at infusion site, or difficulty breathing.,Regular blood tests will be done to monitor your electrolytes and kidney function.,Do not adjust the infusion rate yourself; it is controlled by the healthcare team.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is: Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 m L/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 m L/kg/day of TRAVASOL 3.5%.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is classified as Category C. Amino acid and electrolyte solutions are generally considered low risk for teratogenicity. No specific fetal risks have been identified in animal studies; however, maternal malnutr. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.